Showing results (111-120 of 130) with videos related to

Sort By:
Pageof 13
British Journal of Cancer|August 23, 2018
Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)Nuria Romero-Laorden, Rebeca Lozano, Anuradha Jayaram, et al.
BJU International|January 17, 2013
Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohortChee L Goh, Edward J Saunders, Daniel A Leongamornlert, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkersTimothy A Yap, Li Yan, Amita Patnaik, et al.
Nature Medicine|October 7, 2025
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trialGerhardt Attard, Neeraj Agarwal, Julie N Graff, et al.
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Cancer Research|April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancerGerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
European Urology|December 3, 2014
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate CancerElena Castro, Chee Goh, Daniel Leongamornlert, et al.
European Journal of Cancer (Oxford, England : 1990)|February 24, 2021
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancerRebeca Lozano, Daniela C Salles, Shahneen Sandhu, et al.
Pageof 13